T.Man Pharmaceutical Valuation
Is TMAN-F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of TMAN-F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: TMAN-F (THB18.7) is trading above our estimate of fair value (THB7.95)
Significantly Below Fair Value: TMAN-F is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TMAN-F?
Other financial metrics that can be useful for relative valuation.
What is TMAN-F's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ฿6.92b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.3x |
Enterprise Value/EBITDA | 11.8x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does TMAN-F's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 25.5x | ||
BLC Bangkok Lab And Cosmetic | 19.3x | n/a | ฿3.1b |
MEGA Mega Lifesciences | 16.7x | 11.7% | ฿33.3b |
JSP JSP Pharmaceutical Manufacturing (Thailand) Public | 44.1x | n/a | ฿968.1m |
AFT AFT Pharmaceuticals | 22x | 26.7% | NZ$344.0m |
TMAN-F T.Man Pharmaceutical | 16.5x | n/a | ฿6.9b |
Price-To-Earnings vs Peers: TMAN-F is good value based on its Price-To-Earnings Ratio (16.5x) compared to the peer average (25.3x).
Price to Earnings Ratio vs Industry
How does TMAN-F's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Earnings vs Industry: TMAN-F is good value based on its Price-To-Earnings Ratio (16.5x) compared to the Asian Pharmaceuticals industry average (25.8x).
Price to Earnings Ratio vs Fair Ratio
What is TMAN-F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 16.5x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate TMAN-F's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.